Evaluation of Adverse Events of Oral Antihyperglycaemic Monotherapy Experienced by a Geriatric Population in a Real-World Setting
Authors:
- 1 January 2008
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 25 (7) , 611-622
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001The Diabetes Educator, 2006
- Weight changes following the initiation of new anti‐hyperglycaemic therapiesDiabetes, Obesity and Metabolism, 2006
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus2006
- Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studiesDiabetes, Obesity and Metabolism, 2004
- Guidelines for Improving the Care of the Older Person with Diabetes MellitusJournal of the American Geriatrics Society, 2003
- Glimerpiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experienceClinical Therapeutics, 2003
- Less frequent body weight gain in elderly type 2 diabetic patients treated with glimepirideGeriatrics & Gerontology International, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Insulin and Cognitive Function in an Elderly Population: The Rotterdam StudyDiabetes Care, 1997